Ameritox, Ltd. and Wake Forest University Form Research Partnership

WINSTON SALEM, N.C., Dec. 4, 2012 /PRNewswire/ -- Wake Forest University and Ameritox, Ltd. today announced that Ameritox is supporting research at Wake Forest that could break new ground in developing technologies for medication monitoring and toxicology testing.

"Ameritox, the nation's leader in medication monitoring with a state-of-the-art laboratory in Greensboro, and Wake Forest University are just 25 miles apart, facilitating this cutting edge exploration," said Jay Zimmerman, chief operating officer of Ameritox.

Ameritox pioneered the field of pain medication monitoring, offering physicians tools that give them crucial information to help keep their patients and the communities they live in safe. Wake Forest University is among the nation's top universities, ranked 27th in the most recent U.S. News and World Report "Best Colleges" guide.

The Wake Forest-Ameritox partnership aims to build on the foundation of the science behind the mapping of the human genome to create a new standard in toxicology testing.

"Ameritox is excited to support work with Wake Forest University towards new discoveries for everyday use in commercial toxicology testing and analysis," Zimmerman said. "The researchers and the chemistry department at Wake Forest are recognized nationally for expertise in the science and methods that are advancing the work done in laboratories like those run by Ameritox."

"Wake Forest University has been active in the development of new technologies and analytical methods that have the potential to improve toxicology testing," said Dr. Christa Colyer, chairperson of the Chemistry Department at Wake Forest University. "Being located close to Ameritox's Greensboro laboratories will make it that much easier to collaborate and exchange ideas to realize testing breakthroughs. I am confident that, working with Ameritox, Wake Forest's chemistry department can help to provide even greater overall laboratory performance and success to industry leaders like Ameritox."

About Ameritox
Ameritox is the nation's leader in Pain Medication Monitoring Solutions®, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers the most thorough pain medication monitoring lab process Rx Guardian(SM) with Rx Guardian CD(SM), the only pain medication monitoring process with a proprietary normalization algorithm and a reference database of pain patients clinically assessed for adherence. Patient results are compared against this database, helping physicians assess whether patients are taking their pain medications correctly. Monitoring through prescription drug testing helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at www.ameritox.com, on Twitter @Ameritox, on Facebook at facebook.com/ameritox, and on YouTube at www.youtube.com/ameritox.

© 2012 Ameritox Ltd. All rights reserved. Ameritox, Ameritox-Medication Monitoring Solutions, Rx Guardian, Rx Guardian INSIGHT and Rx Guardian CD are trademarks of Ameritox. Other trademarks are the property of their owners.

About Wake Forest University
Wake Forest University, founded in 1834 and located in Winston-Salem, N.C., is the nation's premier collegiate university. The Wake Forest community embodies the University's motto, Pro Humanitate, or "for humanity," and blends the personal experience of a liberal arts college with the resources of a top research university. The Chemistry Department has a strong tradition of intensive teaching and wide-ranging research in the fundamentals of the field, including analytical chemistry. More information about Chemistry at WFU is available at http://college.wfu.edu/chemistry/ .

SOURCE Ameritox

Back to news